» Articles » PMID: 20345862

Competing Risk of Death: an Important Consideration in Studies of Older Adults

Overview
Specialty Geriatrics
Date 2010 Mar 30
PMID 20345862
Citations 238
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical studies often face the difficult problem of how to account for participants who die without experiencing the study outcome of interest. In a geriatric population with considerable comorbidities, the competing risk of death is especially high. Traditional approaches to describe risk of disease include Kaplan-Meier survival analysis and Cox proportional hazards regression, but these methods can overestimate risk of disease by failing to account for the competing risk of death. This report discusses traditional survival analysis and competing risk analysis as used to estimate risk of disease in geriatric studies. Furthermore, it illustrates a competing risk approach to estimate risk of second hip fracture in the Framingham Osteoporosis Study and compares the results with traditional survival analysis. In this example, survival analysis overestimated the 5-year risk of second hip fracture by 37% and the 10-year risk by 75% compared with competing risk estimates. In studies of older individuals in which a substantial number of participants die during a long follow-up, the cumulative incidence competing risk estimate and competing risk regression should be used to determine incidence and effect estimates. Use of a competing risk approach is critical to accurately determining disease risk for elderly individuals and therefore best inform clinical decision-making.

Citing Articles

A deep-learning retinal aging biomarker for cognitive decline and incident dementia.

Sim M, Tham Y, Nusinovici S, Quek T, Yu M, Xue C Alzheimers Dement. 2025; 21(3):e14601.

PMID: 40042460 PMC: 11881618. DOI: 10.1002/alz.14601.


Correlation of cumulative fasting blood glucose exposure with gastrointestinal cancers: A prospective cohort study.

Liu K, Wang W, Liu Y, Li J, Ma C, Tian Y Medicine (Baltimore). 2025; 104(7):e41529.

PMID: 39960953 PMC: 11835132. DOI: 10.1097/MD.0000000000041529.


Aspirin use reduces cancer risk in betel nut chewers: a nationwide population-based cohort study.

Tien P, Bih Z, Chen W, Shia B, Wu S, Chiang C Am J Cancer Res. 2025; 14(12):5921-5934.

PMID: 39803639 PMC: 11711529. DOI: 10.62347/JXMI9007.


Genomic Medicine in the Developing World: Cancer Spectrum, Cumulative Risk and Survival Outcomes for Lynch Syndrome Variant Heterozygotes with Germline Pathogenic Variants in the and Genes.

Ndou L, Chambuso R, Algar U, Boutall A, Goldberg P, Ramesar R Biomedicines. 2025; 12(12.

PMID: 39767815 PMC: 11672899. DOI: 10.3390/biomedicines12122906.


Cognitive frailty and functional disability in older adults: A 10-year prospective cohort study in Japan.

Chen S, Chen T, Honda T, Kishimoto H, Nofuji Y, Narazaki K Geroscience. 2024; .

PMID: 39627573 DOI: 10.1007/s11357-024-01461-0.


References
1.
Southern D, Faris P, Brant R, Galbraith P, Norris C, Knudtson M . Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol. 2006; 59(10):1110-4. DOI: 10.1016/j.jclinepi.2006.07.002. View

2.
Albertsen P, Hanley J, Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293(17):2095-101. DOI: 10.1001/jama.293.17.2095. View

3.
Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706. DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o. View

4.
Li N, Elashoff R, Li G . Robust joint modeling of longitudinal measurements and competing risks failure time data. Biom J. 2009; 51(1):19-30. PMC: 2726782. DOI: 10.1002/bimj.200810491. View

5.
Pepe M, Mori M . Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?. Stat Med. 1993; 12(8):737-51. DOI: 10.1002/sim.4780120803. View